NCNA - Nucana - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

200.9M

Cash

12.87M

Avg Qtr Burn

-5.497M

Short % of Float

0.10%

Insider Ownership

0.56%

Institutional Own.

22.55%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NUC-3373 (ProTide) combo w/ irinotecan/bevacizumab/oxaliplatin Details Colorectal cancer , Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NUC-7738 (ProTide) +/- pembrolizumab Details Solid tumor/s, Cancer, Melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NUC-3373 (ProTide) combo w/ pembrolizumab Details Solid tumor/s, Cancer, Lung cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Acelarin (NUC-1031) (dFdCTP) Details Cancer, Biliary Tract Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.